Amgen v. Sanofi
In brief
Amgen's broad antibody claims were invalid because its patents did not teach skilled people how to make and use all they covered.
- Where it stands
- Decided
Decided 9-0 · May 18, 2023 · Opinion by Justice Gorsuch
- What it’s about
- In a unanimous decision, the Supreme Court ruled that two of Amgen's patents for cholesterol-lowering drugs were invalid because they were too broad.
- Who it affects
- Patent applicants cannot claim an entire class of products without teaching others how to make and use that class. Drug companies seeking broad antibody patents are directly affected.
Summary: written with AI from the case record.
What it's about
The Court found the patents failed to satisfy the Patent Act's enablement clause by claiming an entire class of antibodies without providing enough detail for a skilled person to make and use them.
The decision applies the Patent Act's requirement that a patent explain an invention clearly enough for skilled people in the field to use it.
Question presented
Whether the standard for determining the adequacy of the "written description of the invention" in a patent must be "in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains . ."?
What the Court decided
Holding
The courts below correctly concluded that Amgen failed “to enable any person skilled in the art . . . to make and use the [invention]” as defined by the relevant claims. 987 F. 3d 1080, affirmed.
- Result
- Affirmed
The vote
From the opinions
“to enable any person skilled in the art . . . to make and use the [invention]”
What's next
Lower courts will apply the decision when testing whether broad patent claims provide enough practical instruction. Patent applicants, including drug companies, may need to provide more detail supporting wide-ranging claims.
Documents
Docket activity
New analysis added
AI analysis generated: Impact Analysis
AI analysis generated: Opinion Summary
New analysis added
AI analysis generated: Case Briefing
Show 5 moreShow fewer
AI analysis generated: Decision Record
Opinion added: Sanofi
Opinion added: opinion
Brief added: Petition
Brief added: Questions Presented
More questions
- What did the Supreme Court rule in Amgen v. Sanofi?
- The Court affirmed that Amgen's two patents were invalid. They did not enable skilled people to make and use the entire antibody class claimed.
- Who won Amgen v. Sanofi?
- Sanofi won. The Court unanimously affirmed the lower courts' conclusion that Amgen's patent claims did not meet the Patent Act's requirement.
- What does Amgen v. Sanofi mean for drug companies?
- Drug companies seeking broad antibody patents must provide enough instruction to support the full scope of their claims. Broad claims alone are not enough.
- Is the patent enablement requirement still the law after Amgen v. Sanofi?
- Yes. The Court applied the Patent Act's requirement that patents enable skilled people to make and use the claimed invention.
- What happens next after Amgen v. Sanofi?
- Lower courts will use this decision in patent disputes involving broad claims. Patent applicants may revise applications to include more detailed technical teaching.
Sources
Primary materials plus reporting. Best-effort analysis: this explainer relies on a mix of primary materials and trusted secondary sources. Official filings and opinions remain authoritative.